NeVa Retrospective Comparative SR Study

N/AActive Not RecruitingNCT06964724

Vesalio800 enrolled

Overview

To compare safety and effectiveness of NeVa Stent Retriever (SR) to Control SR in the treatment of stroke caused by large vessel occlusion. The main questions it aims to answer are: How do recanalization rates for NeVa SR compare with those of the Control SR? How does NeVa SR safety compare with Control SR safety?

NITRO is a multicenter, retrospective, comparative, non-inferiority, cohort study designed to compare NeVa SR with Control SR for safety and effectiveness when removing thrombus in subjects presenting with acute ischemic stroke (AIS) due to large vessel occlusion (LVO). The objective of the NeVa International, Multi-center, Retrospective Comparative stent retriever (SR) study (NITRO) study is to compare safety and effectiveness of the NeVa SR to commonly used SR with CE-mark, and US FDA clearance, to restore blood flow in patients experiencing acute ischemic stroke due to large intracranial vessel occlusion. NITRO aims to collect data describing real-world clinical practices when using SRs according to their indicated use within the indicated population. As such, the eligibility criteria define patients who are diagnosed with AIS and are indicated for endovascular MT aligning to the target population for the proposed device. The present study will include data from subjects treated with either NeVa SR or one of the Control SR. Control SR will include any SR commonly used in thrombectomy trials as first-line strategies and which represent CE-mark, and US FDA cleared stent retrievers.

Study Type

OBSERVATIONAL

Enrollment

800

Conditions

Stroke Acute

Interventions

Mechanical thrombectomyPROCEDURE

Mechanical thrombectomy with stent retriever

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Treatment during the enrollment period * Age ≥18 * Baseline modified Thrombolysis in Cerebral Infarction (mTICI) score ≤ 1 * Pre-stroke modified Rankin score (mRS) of 0 or 1 * Internal Carotid Artery (ICA), Middle Cerebral Artery (first segment M1/ second segment M2), basilar artery or vertebral artery occlusion * National Institutes of Health Stroke Scale (NIHSS) score ≥ 8 and ≤ 25 * Thrombectomy procedure initiated within 8h of Time Last Known Well (TLKW) * Intravenous Tissue Plasminogen Activator (IV-tPA) failed, given within 3h of TLKW, or ineligibility for thrombolytic drug Exclusion Criteria: * First line contact aspiration alone or non-study device as first-line device

Locations (5)

Hospital Espanol de Mendoza

Mendoza, Argentina

CHU LIege

Liège, Belgium

UK Munster

Münster, Germany

Republican Vilnius University Hospital

Vilnius, Lithuania

İstanbul Aydrn Üniversitesi

Outcomes

Primary Outcomes

Reperfusion Effectiveness

Number of patients with a Modified Thrombolysis in cerebral infarction (mTICI) ≥2B and mTICI≥2C recanalization after 1st pass and at end of procedure

Time frame: Procedural

Secondary Outcomes

Procedural symptomatic bleeding events

Number of patients experiencing symptomatic intracranial hemorrhage (sICH)

Time frame: Within 24 hours post intervention

Procedure Safety

Number of patients experiencing procedure related serious Adverse Events (PRSAE)

Time frame: Within 24 hours post intervention

Device relationship to serious adverse events

Number of patients experiencing a serious adverse device effect (SADE)

Time frame: Within 24 hours post intervention

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.